Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract 75N95019D00031
Award Date
9/26/19
Last Date to Order
9/25/26
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
Contract IDVs
Contract Awards
2
Transactions
1
Price Lists
Opportunity Stack
1
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Regents Of The University Of Minnesota
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
CRO Support for NCATS Medicinal Chemistry for Lead Optimization
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Service Contract Inventory
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
CRO Support for NCATS Medicinal Chemistry for Lead Optimization
Master IDIQ
75N95019D00031
Indefinite Delivery Contract
2
Federal Contract Awards
Description
CRO SUPPORT FOR NCATS MEDICINAL CHEMISTRY FOR LEAD OPTIMIZATION.
Posted 9/23/19, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00001
CRO SUPPORT FOR NCATS MEDICINAL CHEMISTRY FOR LEAD OPTIMIZATION.
Supplemental Agreement for work within scope
$0
8/28/23
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order 75N95019D00031-75N95022F00001
The Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, has been awarded a $1,688,646 delivery order against the Cooperative Research and Development Agreement Support for the National Center for Advancing Translational Sciences Medicinal Chemistry for Lead Optimization master indefinite-delivery/indefinite-quantity contract by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse. The products and services provided under this contract are synthetic chemistry support for the Therapeutics Discovery Branch medicinal chemistry team to support drug discovery and development efforts. The period of performance is from September 28, 2022 through September 27, 2024 in Minneapolis, Minnesota. Pricing is set at cost, with no fee applied.
Regents Of The University Of Minnesota
$1.7m
9/28/22
9/27/24
8/28/23
Delivery Order 75N95019D00031-75N95019F00088
This is a federal contract award issued by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to the Regents of the University of Minnesota. The contract, valued at $1,725,318.18, is a Delivery Order under the NCATS "CRO Support for NCATS Medicinal Chemistry for Lead Optimization" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The work involves the development of a D3 antagonist for substance use disorder (SUD) treatment. The contract does not have a set-aside designation. The Regents of the University of Minnesota, through its Office of Sponsored Projects Administration, is the prime contractor and will be conducting the research and development work at its facilities in Minneapolis, Minnesota. This contract award leverages the university's expertise in cardiovascular research, epidemiology, and other scientific disciplines to support the NCATS mission of advancing translational sciences.
Regents Of The University Of Minnesota
$1.7m
9/26/19
11/25/24
11/26/24
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
CRO Support for NCATS Medicinal Chemistry for Lead Optimization
SUMMARY This is a notice of a proposed contract action issued in accordance with FAR 5.203(a). The Government intends to issue RFP No. N01TR-19-2006, titled "CRO Support for NCATS Medicinal Chemistry for Lead Optimization," via FedBizOpps on or about November 21, 2018. REQUIREMENT AND TYPE OF SERVICE The Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development. The objective of this contract is to support the DPI drug development programs by identifying preclinical drug candidates with improved efficacy, optimized ADME properties, and minimal predicted toxicity. One of the DPI program requirements is to efficiently identify preclinical development candidates for rare and neglected diseases. To accomplish this endeavor, DPI has a need for a team of chemists; pharmacologists; absorption, distribution, metabolism, and excretion (ADME)/pharmacokinetics (PK) experts; and toxicologists working closely together to perform medicinal chemistry lead optimization. While this Contract will be primarily in support of the DPI drug development programs. The Government reserves the right to allow other drug development programs at NIH to solicit task order proposals. As such, this Contract is not limited to rare or neglected disorders. RELEASE OF SOLICITATION The Government intends to issue a Request for Proposals on or about November 21, 2018. Proposals will be due 45 calendar days following release of the RFP. The Government anticipates making multiple Indefinite Delivery/Indefinite Quantity (ID/IQ) type contract awards -with the eventual contracts being administered and funded via Task Orders (TOs). The ultimate goal of DPI and this planned project is to bring new drugs to market. To this end, the Government has issued a Determination of Exceptional Circumstances (DEC) to deviate from the Federal Acquisition Regulation clauses at 52.227-11 Patent Rights and 52.227-14 Rights in Data. The deviated language enables DPI contributors to retain control of their intellectual property and will be included in the RFP and incorporated in any resultant contract. Prospective Offerors are advised that agreement to the terms of these FAR clauses deviations will be a condition for contract award. This is a new requirement; therefore, no incumbent information is provided. The Government will select proposals that are most advantageous to the Government in accordance with the basis of award included in the solicitation. The Government anticipates awards will be made in the fourth quarter of FY2019. ABOUT DPI AND NCATS The Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) conducts translational research in human therapeutics development and aims to move small molecule and biologic drug candidates forward in the drug development pipeline to predetermined milestones, at which point, DPI will hand off the drug candidate to external partner(s) to bring the novel therapy to patients. In addition to developing new candidate drugs, DPI seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial pre-clinical stage of drug development. DPI's model is to operate as a full range small molecule and biologics drug development organization, moving drug candidates through each phase of the pre-clinical drug development process until an Investigational New Drug (IND) is filed with the US Food and Drug Administration (FDA). DPI conducts drug development as collaborations through programs such as the Therapeutics for Rare and Neglected Diseases (TRND) and the Bridging Interventional Development Gaps (BrIDGs) programs. DPI drug development programs originate from academia, industry, non-profit foundations, or internally from NCATS and other NIH Institutes, and its research and development (R & D) operational strategy is to combine the capabilities of DPI in-house staff and DPI partners, who may be the drug originators. Each drug program operates in a multi-disciplinary, multi-partnership matrix team environment, and a DPI program officer is responsible for the overall planning, execution, and reporting of the program. Contract research organizations (CROs) and contract manufacturing organizations (CMOs) provide DPI with manufacturing, pharmacology, toxicology, regulatory, and clinical operations services to assist with drug development. Planning and execution of each individual drug development program includes identification of scientific areas best suited for utilization of CROs and CMOs to conduct some or all parts of a given drug development program. CONTRACTING OFFICE ADDRESS NCATS Section NIDA Office of Acquisition, NIH 6001 Executive Blvd Suite 3287, MSC 9534 Bethesda, MD 20892-9534 * * Use Rockville, MD 20852 for FedEx/USPS/Courier/Hand Delivery.
N01TR-19-2007
Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
Award Notice 1/1
11/6/18, 11:22 AM